Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Single Dose, Crossover Bioequivalent Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap, 25mg in Healthy Male Volunteers

NCT03208218 is registered in ClinicalTrials.gov with Samyang Biopharmaceuticals Corporation as lead sponsor.

NCT NCT03208218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03208218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Single Dose, Crossover Bioequivalent Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap, 25mg in Healthy Male Volunteers
Lead sponsor
Samyang Biopharmaceuticals Corporation
Phase
Phase 1
Overall status
Completed
Start date
August 17, 2016
Completion date
October 31, 2016
Enrollment
42 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, male